Previous 10 | Next 10 |
Summary Arcellx, Inc. produced excellent data for their ddBCMA program. The data helped clinch a deal with Gilead. Arcellx goes up against Johnson & Johnson's formidable carvykti, but now it has help. Arcellx, Inc. ( ACLX ) is up 83% since my bullish coverage f...
Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors of Arcellx (NASDAQ: ACLX ) stock are in a great mood today, and the reason is no mystery. Acrellx just disclosed that it’s teaming with biopharmaceutical giant Gilead Sciences (NASDAQ: GILD ). Together,...
Arcellx ( NASDAQ: ACLX ) on Friday said it would co-develop and co-commercialize its lead late-stage product candidate CART-ddBCMA for the treatment of multiple myeloma with Kite, a Gilead Sciences ( NASDAQ: GILD ) company. Under the global strategic collaboration, ACLX wi...
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress PR Newswire -- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses o...
-- Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing -- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to ...
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma PR Newswire -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading...
Arcellx press release ( NASDAQ: ACLX ): Q3 GAAP EPS of -$2.12. As of September 30, 2022, Arcellx had cash, cash equivalents, and marketable securities of $280.8 million, which is anticipated to fund its operations for at least the next 12 months. For further details ...
Arcellx Reports Third Quarter 2022 Financial Results and Business Progress PR Newswire -- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA -- -- Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 6...
The following slide deck was published by Arcellx, Inc. in conjunction with this event. For further details see: Arcellx (ACLX) Corporate Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...